BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, March 29, 2024
See today's BioWorld
Home
» Da Volterra to smite the might of C. diff. with antibiotic adsorption technology
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Da Volterra to smite the might of C. diff. with antibiotic adsorption technology
Sep. 26, 2017
By
Cormac Sheridan
No Comments
DUBLIN – Paris-based anti-infectives developer Da Volterra SA is planning a phase II trial of its lead product, DAV-132, in Europe in the coming months and is also looking to open an IND in the U.S. shortly.
BioWorld